Maklumat Ubat dan Panduan Rawatan

Gilteritinib Maintenance Therapy After Transplantation in Patients With FLT3-ITD AML Who Have Measurable Residual Disease The ASCO Post

Managing post-transplant relapse in FLT3-mutated AML with gilteritinib | Rzetelska | Acta Haematologica Polonica Via Medica Journals

Long-term partial response in a patient with liver metastasis of primary adrenocortical carcinoma with adjuvant mitotane plus transcatheter arterial chemoembolization and microwave…

Retsevmo is a cancer medicine for use in patients whose cancer is caused by certain changes in a gene called RET, leading to the production of abnormal RET proteins.

Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 17, Status: Authorised